Get the Stockscreener App
5.62
0.35%
0.03
Personalis Inc stock is traded at $5.62, with a volume of 381.01K.
It is up +0.35% in the last 24 hours and down -14.49% over the past month.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.
See More
Previous Close:
$5.59
Open:
$5.49
24h Volume:
381.01K
Relative Volume:
0.34
Market Cap:
$495.50M
Revenue:
$73.48M
Net Income/Loss:
$-108.30M
P/E Ratio:
-2.4978
EPS:
-2.25
Net Cash Flow:
$-67.17M
1W Performance:
-16.40%
1M Performance:
-14.49%
6M Performance:
+7.46%
1Y Performance:
+62.59%
1-Day Range:
$5.41
$5.6385
1-Week Range:
$5.41
$6.70
52-Week Range:
$2.81
$7.79
Personalis Inc Stock (PSNL) Company Profile
Name
Personalis Inc
Sector
Industry
Phone
650-752-1300
Address
6600 DUMBARTON CIRCLE, FREMONT, CA
Compare PSNL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PSNL
Personalis Inc
|
5.61 | 492.85M | 73.48M | -108.30M | -67.17M | -2.25 |
|
TMO
Thermo Fisher Scientific Inc
|
481.07 | 182.01B | 43.21B | 6.58B | 6.17B | 17.29 |
|
DHR
Danaher Corp
|
201.97 | 148.12B | 24.01B | 3.41B | 4.86B | 4.70 |
|
IDXX
Idexx Laboratories Inc
|
546.88 | 46.09B | 3.93B | 894.97M | 837.70M | 10.82 |
|
A
Agilent Technologies Inc
|
117.78 | 34.04B | 6.63B | 1.17B | 1.19B | 4.05 |
|
IQV
Iqvia Holdings Inc
|
190.53 | 33.07B | 15.50B | 1.33B | 2.16B | 7.34 |
Personalis Inc Stock (PSNL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-15-25 | Initiated | Guggenheim | Buy |
| Mar-17-25 | Initiated | Craig Hallum | Buy |
| Feb-06-23 | Upgrade | Needham | Hold → Buy |
| Jan-07-22 | Upgrade | BofA Securities | Neutral → Buy |
| Nov-05-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-03-21 | Downgrade | Needham | Buy → Hold |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Sep-20-21 | Reiterated | Needham | Buy |
| May-06-21 | Upgrade | Oppenheimer | Perform → Outperform |
| Jan-28-21 | Initiated | Truist | Buy |
| Jan-04-21 | Downgrade | BofA Securities | Buy → Neutral |
| Nov-12-20 | Reiterated | Needham | Buy |
| Nov-06-20 | Downgrade | Oppenheimer | Outperform → Perform |
| Oct-19-20 | Initiated | Citigroup | Buy |
| Oct-08-20 | Initiated | BTIG Research | Buy |
| Aug-27-20 | Initiated | H.C. Wainwright | Buy |
| Aug-18-20 | Initiated | Needham | Buy |
| Sep-26-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Jul-15-19 | Initiated | BofA/Merrill | Neutral |
| Jul-15-19 | Initiated | Cowen | Outperform |
| Jul-15-19 | Initiated | Morgan Stanley | Overweight |
| Jul-15-19 | Initiated | Oppenheimer | Outperform |
View All
Personalis Inc Stock (PSNL) Latest News
What the charts say about Personalis Inc. todayFree Smart Trade Plans With Risk Protection - Newser
What makes Personalis Inc. stock price move sharplyFree Weekly Growth Stock Entry Point Alerts - Newser
Insiders Relieved After Selling Personalis With 13% Price Dip - simplywall.st
Why Personalis Inc. stock attracts strong analyst attentionAI Forecast for Trending Stocks Indicates Upside - beatles.ru
Regression analysis insights on Personalis Inc. performanceFree Fast Return Equity Trade Forecast - Newser
Personalis Inc. stock momentum explainedDividend Strategy Summary With 10-Year Outlook - Newser
Reversal indicators forming on Personalis Inc. stockSteady Return Plan Based on Data Analysis - Newser
Why Personalis Inc. is moving todayReal Trader Watchlist with Entry Targets - Newser
Tick level data insight on Personalis Inc. volatilityInvestment Roadmap for High Potential Stocks - Newser
New Product Launches: Will They Boost Personalis Inc. Stock in 2025Trade Insight With Community Collaboration Supported - metal.it
What's the outlook for PSNL's Q1 2025 earnings? - AInvest
Will earnings trigger a reversal in Personalis Inc.Free Reliable Chart-Based Trade Entries - Newser
Personalis, Inc. (NASDAQ:PSNL) Receives Consensus Rating of “Buy” from Analysts - Defense World
Traders Consider Averaging Down in Personalis Inc.Real Time Alerts Based on AI Prediction Triggered - metal.it
Quant Funds Rotate Into Personalis Inc. StockValue Investing Picks With Stability Outlined - metal.it
How many analysts rate Personalis Inc. as a “Buy”Achieve breakthrough gains with smart trades - jammulinksnews.com
What institutional investors are buying Personalis Inc. stockUnlock your trading potential today - jammulinksnews.com
Multi factor analysis applied to Personalis Inc. Conservative Asset Allocation Risk Analysis - Newser
How does Personalis Inc. compare to its industry peersDiscover undervalued stocks ready to soar - jammulinksnews.com
How does Personalis Inc. generate profit in a changing economyAchieve rapid financial growth with expert help - jammulinksnews.com
Top Risks to Consider Before Buying Personalis Inc. StockFree Predictions - Newser
Why Personalis Inc. stock is on top investor watchlistsOutstanding capital appreciation - jammulinksnews.com
What analysts say about Personalis Inc. stockHigh-yield capital appreciation - PrintWeekIndia
What drives Personalis Inc. stock priceHigh-return market picks - Autocar Professional
Is Personalis Inc. a good long term investmentDynamic profit opportunities - Autocar Professional
Personalis to Announce Second Quarter 2025 Financial Results - BioSpace
Personalis Inc. Stock Analysis and ForecastMassive stock growth - jammulinksnews.com
Personalis Inc Stock (PSNL) Financials Data
Revenue
Net Income
Cash Flow
EPS
Personalis Inc Stock (PSNL) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Tachibana Aaron | CFO AND COO |
Jul 28 '25 |
Sale |
6.57 |
641 |
4,211 |
164,458 |
| Tachibana Aaron | CFO AND COO |
May 16 '25 |
Sale |
4.95 |
1,291 |
6,390 |
165,099 |
| Moore Stephen Michael | SVP and Chief Legal Officer |
May 16 '25 |
Sale |
4.95 |
1,675 |
8,291 |
64,200 |
| Chen Richard | CHIEF MEDICAL OFFICER AND EVP |
May 16 '25 |
Sale |
4.95 |
910 |
4,504 |
124,957 |
| Tachibana Aaron | CFO AND COO |
Jan 28 '25 |
Sale |
5.79 |
708 |
4,099 |
166,390 |
| Chen Richard | CHIEF MEDICAL OFFICER AND EVP |
Jan 28 '25 |
Sale |
5.79 |
519 |
3,005 |
123,367 |
| Chen Richard | CHIEF MEDICAL OFFICER AND EVP |
Dec 16 '24 |
Sale |
3.82 |
4,834 |
18,466 |
123,886 |
| Moore Stephen Michael | SVP and Chief Legal Officer |
Dec 16 '24 |
Sale |
3.82 |
1,513 |
5,780 |
65,875 |
| Tachibana Aaron | CFO AND COO |
Dec 16 '24 |
Sale |
3.82 |
6,865 |
26,224 |
167,098 |
| Tachibana Aaron | CFO AND COO |
Nov 18 '24 |
Sale |
3.79 |
1,307 |
4,954 |
173,963 |
0.27%
0.52%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):